Анастасія С. Лунько
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Анастасія С. Лунько has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Sergii V. Konovalenko
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
4 shared publications - Tetiana A. Lunko
Odesa National Medical University, Odesa, Ukraine
4 shared publications - Anna V. Khmel
Specialized Mammological Center, Kyiv, Ukraine
3 shared publications - Alla Volyanska
Odesa national medical university, Odesa
2 shared publications - Dmytro S. Androsov
O.F. Herbachevsky Zhytomyr Regional Clinical Hospital, Zhytomyr, Ukraine
2 shared publications - Igor Z. Gladchuk
Odesa national medical university, Odesa
2 shared publications
Latest Publications
- Open Access
- 28 February 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (1) , 28-34
Histological landmarks for choosing a therapeutic route in patients with overlap syndrome of genital endometriosis and benign breast disease
Background. Genital endometriosis (GE) remains a very common disease, occurring in 0.5–5 % of fertile women and in 25–40 % of infertile women. Benign breast diseases (BBD) are common throughout life, from early reproductive age to the postmenopausal period, making them a potential health problem for a large number of women. The histological characteristics of endometrial and breast tissues in patients suffering from the overlap syndrome of GE and BBD are of interest, since this condition carries an increased risk of endometrial, ovarian and breast cancer. The purpose was to study and identify the most characteristic features of endometrioid tissue and ductal hyperplasia tissue of the breast in women with overlap syndrome of GE and BBD using light microscopy. Materials and methods. Histological preparations of endometrioid foci and breast hyperplasia tissues of 148 women with overlap syndrome of GE and BBD were studied. The material was obtained by the method of fine-needle aspiration puncture biopsy, which was performed under ultrasound control. Cytological analysis and microphotography were performed using an Olympus CX23 microscope with different magnifications (×40, ×100 (immersion)). Results. The study showed that in the selected cohort of patients with overlap syndrome of GE and BBD, most histological samples showed proliferative activity of mesothelial cells. At the same time, morphological signs of atypia of cellular elements of atypical ductal hyperplasia were observed in 47.3 % of histological samples of breast tissue. Cells with signs of malignant transformation were not found in any of the provided breast tissue samples. It is important to note that in 15 % of patients, histological signs of malignancy were found in endometrial samples, which led to their immediate referral to a gynecological oncologist for surgical intervention and the necessary adjuvant therapy. Conclusions. In the prognosis of the clinical course of GE and BBD overlap syndrome, histological confirmation of the diagnosis and detection of signs of atypia in biopsy samples play a key role. The finding of atypical cells requires clinical consultation with the participation of a gynecologist, a mammologist and a gynecological oncologist, during which a decision is made regarding surgical intervention and the necessary pharmacotherapy.
- 28 February 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (1) , 28-34
Open AccessHistological landmarks for choosing a therapeutic route in patients with overlap syndrome of genital endometriosis and benign breast disease
Background. Genital endometriosis (GE) remains a very common disease, occurring in 0.5–5 % of fertile women and in 25–40 % of infertile women. Benign breast diseases (BBD) are common throughout life, from early reproductive age to the postmenopausal period, making them a potential health problem for a large number of women. The histological characteristics of endometrial and breast tissues in patients suffering from the overlap syndrome of GE and BBD are of interest, since this condition carries an increased risk of endometrial, ovarian and breast cancer. The purpose was to study and identify the most characteristic features of endometrioid tissue and ductal hyperplasia tissue of the breast in women with overlap syndrome of GE and BBD using light microscopy. Materials and methods. Histological preparations of endometrioid foci and breast hyperplasia tissues of 148 women with overlap syndrome of GE and BBD were studied. The material was obtained by the method of fine-needle aspiration puncture biopsy, which was performed under ultrasound control. Cytological analysis and microphotography were performed using an Olympus CX23 microscope with different magnifications (×40, ×100 (immersion)). Results. The study showed that in the selected cohort of patients with overlap syndrome of GE and BBD, most histological samples showed proliferative activity of mesothelial cells. At the same time, morphological signs of atypia of cellular elements of atypical ductal hyperplasia were observed in 47.3 % of histological samples of breast tissue. Cells with signs of malignant transformation were not found in any of the provided breast tissue samples. It is important to note that in 15 % of patients, histological signs of malignancy were found in endometrial samples, which led to their immediate referral to a gynecological oncologist for surgical intervention and the necessary adjuvant therapy. Conclusions. In the prognosis of the clinical course of GE and BBD overlap syndrome, histological confirmation of the diagnosis and detection of signs of atypia in biopsy samples play a key role. The finding of atypical cells requires clinical consultation with the participation of a gynecologist, a mammologist and a gynecological oncologist, during which a decision is made regarding surgical intervention and the necessary pharmacotherapy.
- Open Access
- 13 February 2026
- Published by Professional Event, LLC in Reproductive health of woman
- No. 1,p. 58-63
The symptom-modifying effect of dienogest in patients with genital endometriosis who have proliferative changes in the mammary glands
Modern studies show that in different countries 15–70% of patients with genital endometriosis (GE) have concomitant breast pathology, which is considered a manifestation of overlap syndrome. This category of patients requires a detailed examination of the mammary glands when choosing hormonal therapy, as well as more careful observation during treatment.The objective: to assess the symptom-modifying effect of dienogest in patients with GE who have proliferative changes in the mammary glands.Materials and methods. 226 women of reproductive age with GE were examined. Staging of endometriosis was performed according to the revised version of the American Society of Reproductive Medicine classification after laparoscopic intervention. Diagnosis, treatment and clinical monitoring of patients were carried out in compliance with modern bioethical requirements, as well as in accordance with the recommendations of the World Health Organization and the American College of Obstetricians and Gynecologists. All patients had ultrasound examination of the mammary glands. Changes in functional status were assessed using the Breast imaging reporting and data system (BI-RADS) scale. Endopain questionnaire was used to determine the intensity of pain syndrome in GE. As a symptom-modifying drug, patients were prescribed dienogest 2 mg once a day for 24 weeks. The presence of clinical manifestations of GE was determined before and after treatment.Results. Proliferative changes in the tissues of the mammary gland were detected in 65.6% of the examined patients with GE. As the stage of endometriosis progresses, the severity of proliferative changes in the mammary glands increases (positive correlation of medium strength with the stage of external GE was found, r = 0.53; p < 0.05). In the selected cohort of patients, the use of dienogest 2 mg for 6 months led to a decrease in the intensity, and in many cases to the disappearance of chronic pelvic pain syndrome and other manifestations of the disease: algodysmenorrhea and dyspareunia.Conclusions. The study confirmed the world data that the overlap syndrome of GE and dyshormonal breast diseases is a common clinical phenomenon. It has been established that with increasing stage of endometriosis, there is an increase in the breast pathologies frequency. In the treatment of patients with overlap syndrome of GE and dyshormonal breast diseases, the effectiveness of dienogest has been confirmed, as evidenced by the regression of clinical symptoms of GE, in particular, a decrease in the intensity of chronic pelvic pain syndrome. It is important that hormonal therapy for endometriosis has demonstrated a high safety profile, because it not only does not provoke the occurrence of side effects, but also does not have an undesirable effect on the functional state of the mammary glands.
- 13 February 2026
- Published by Professional Event, LLC in Reproductive health of woman
- No. 1,p. 58-63
Open AccessThe symptom-modifying effect of dienogest in patients with genital endometriosis who have proliferative changes in the mammary glands
Modern studies show that in different countries 15–70% of patients with genital endometriosis (GE) have concomitant breast pathology, which is considered a manifestation of overlap syndrome. This category of patients requires a detailed examination of the mammary glands when choosing hormonal therapy, as well as more careful observation during treatment.The objective: to assess the symptom-modifying effect of dienogest in patients with GE who have proliferative changes in the mammary glands.Materials and methods. 226 women of reproductive age with GE were examined. Staging of endometriosis was performed according to the revised version of the American Society of Reproductive Medicine classification after laparoscopic intervention. Diagnosis, treatment and clinical monitoring of patients were carried out in compliance with modern bioethical requirements, as well as in accordance with the recommendations of the World Health Organization and the American College of Obstetricians and Gynecologists. All patients had ultrasound examination of the mammary glands. Changes in functional status were assessed using the Breast imaging reporting and data system (BI-RADS) scale. Endopain questionnaire was used to determine the intensity of pain syndrome in GE. As a symptom-modifying drug, patients were prescribed dienogest 2 mg once a day for 24 weeks. The presence of clinical manifestations of GE was determined before and after treatment.Results. Proliferative changes in the tissues of the mammary gland were detected in 65.6% of the examined patients with GE. As the stage of endometriosis progresses, the severity of proliferative changes in the mammary glands increases (positive correlation of medium strength with the stage of external GE was found, r = 0.53; p < 0.05). In the selected cohort of patients, the use of dienogest 2 mg for 6 months led to a decrease in the intensity, and in many cases to the disappearance of chronic pelvic pain syndrome and other manifestations of the disease: algodysmenorrhea and dyspareunia.Conclusions. The study confirmed the world data that the overlap syndrome of GE and dyshormonal breast diseases is a common clinical phenomenon. It has been established that with increasing stage of endometriosis, there is an increase in the breast pathologies frequency. In the treatment of patients with overlap syndrome of GE and dyshormonal breast diseases, the effectiveness of dienogest has been confirmed, as evidenced by the regression of clinical symptoms of GE, in particular, a decrease in the intensity of chronic pelvic pain syndrome. It is important that hormonal therapy for endometriosis has demonstrated a high safety profile, because it not only does not provoke the occurrence of side effects, but also does not have an undesirable effect on the functional state of the mammary glands.
- Open Access
- 20 November 2025
- Published by Publishing House Zaslavsky in EMERGENCY MEDICINE
- Vol. 21 (7) , 725-730
The effectiveness of iron deficiency nutritional correction in patients with genital endometriosis accompanied by mild anemia
Background. Women with endometriosis are at higher risk of developing iron deficiency than those without endometriosis. The results of many studies indicate that iron deficiency should be considered during the initial diagnosis and subsequent treatment of endometriosis, since menstrual disorders with the simultaneous presence of endometrioid heterotopias are one of the factors for the development of anemia in women. The purpose was to study the effectiveness of nutritional correction of iron deficiency in patients with genital endometriosis accompanied by dysmenorrhea. Materials and methods. Endometriosis patients with mild anemia were prescribed nutritional correction of iron deficiency. In the study group (n = 34), women received a complex of microencapsulated iron pyrophosphate (14 mg) in liposomal form with folic acid (200 μg), vitamin B12 (2.5 μg) and vitamin C (80 mg), as well as a dietary supplement of lactoferrin at a dose of 250 mg per day for 2 months; in the comparison group (n = 32), the above-mentioned combination drug was administered without adding lactoferrin to the diet. The patients were assessed for the following indicators: hemoglobin level, erythrocyte count, ferritin levels, transferrin and total serum iron concentration before treatment and after 2 months. Results. Nutritional correction of iron deficiency in patients with endometriosis accompanied by mild anemia with the use of a complex of iron pyrophosphate and vitamins is not only effective, but also safe, because no side effects of diet therapy were recorded. Adding the dietary supplement lactoferrin to the iron-vitamin preparation improves restoration of the iron metabolism level and normalizes its key indicators: hemoglobin, ferritin and serum iron, and leads to a more significant increase in transferrin. It is also important that the mean corpuscular hemoglobin concentration in the study group reached normal, while in the comparison group, it only approached normal values. Conclusions. Lactoferrin in combination with an iron-vitamin complex can provide the most favorable conditions for the absorption of the required amount of iron against the background of a decrease in the inflammation and normalization of the microbiota. Due to its affinity for transferrin, lactoferrin participates in the full restoration of the proper level of iron metabolism, which is consistent with the data of other studies in recent years.
- 20 November 2025
- Published by Publishing House Zaslavsky in EMERGENCY MEDICINE
- Vol. 21 (7) , 725-730
Open AccessThe effectiveness of iron deficiency nutritional correction in patients with genital endometriosis accompanied by mild anemia
Background. Women with endometriosis are at higher risk of developing iron deficiency than those without endometriosis. The results of many studies indicate that iron deficiency should be considered during the initial diagnosis and subsequent treatment of endometriosis, since menstrual disorders with the simultaneous presence of endometrioid heterotopias are one of the factors for the development of anemia in women. The purpose was to study the effectiveness of nutritional correction of iron deficiency in patients with genital endometriosis accompanied by dysmenorrhea. Materials and methods. Endometriosis patients with mild anemia were prescribed nutritional correction of iron deficiency. In the study group (n = 34), women received a complex of microencapsulated iron pyrophosphate (14 mg) in liposomal form with folic acid (200 μg), vitamin B12 (2.5 μg) and vitamin C (80 mg), as well as a dietary supplement of lactoferrin at a dose of 250 mg per day for 2 months; in the comparison group (n = 32), the above-mentioned combination drug was administered without adding lactoferrin to the diet. The patients were assessed for the following indicators: hemoglobin level, erythrocyte count, ferritin levels, transferrin and total serum iron concentration before treatment and after 2 months. Results. Nutritional correction of iron deficiency in patients with endometriosis accompanied by mild anemia with the use of a complex of iron pyrophosphate and vitamins is not only effective, but also safe, because no side effects of diet therapy were recorded. Adding the dietary supplement lactoferrin to the iron-vitamin preparation improves restoration of the iron metabolism level and normalizes its key indicators: hemoglobin, ferritin and serum iron, and leads to a more significant increase in transferrin. It is also important that the mean corpuscular hemoglobin concentration in the study group reached normal, while in the comparison group, it only approached normal values. Conclusions. Lactoferrin in combination with an iron-vitamin complex can provide the most favorable conditions for the absorption of the required amount of iron against the background of a decrease in the inflammation and normalization of the microbiota. Due to its affinity for transferrin, lactoferrin participates in the full restoration of the proper level of iron metabolism, which is consistent with the data of other studies in recent years.
- Open Access
- 25 September 2025
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Ukrainian educational and scientific medical space
- No. 1,p. 67-75
ETIOPATHOGENETIC JUSTIFICATION OF ENDOMETRIOSIS IMMUNOTHERAPY
Introduction. Genital endometriosis (GE) remains a fairly common disease, occurring in 0.5-5% of fertile women and in 25-40% of infertile women. In modern studies, the ability of endometrioid foci to actively resist immune surveillance, which causes changes in the behavior of regulatory cells: T-lymphocytes and macrophages, attracts attention. Aim. Using data from modern literary sources, to study the role of the immunological component in the etiology and pathogenesis of endometriosis and to outline the prospects for immunotherapeutic approaches to solving the problem. Materials and methods. The search and selection of publications, systematic reviews and current recommendations was carried out using the PubMed and Google Scholar databases. Abstracts of publications were studied and articles that did not meet the study criteria were excluded. The full texts of the selected articles were examined for compliance with the study criteria. Results. Ectopic endometrial cells, creating a new microenvironment around themselves and launching protective mechanisms against attacks by lymphocytes and macrophages, demonstrate to us how living microstructures are able to adapt and survive in unusual, even extreme, conditions. In connection with the key role of the immune system in the pathogenesis of GE established in studies, the pathogenetic significance of immunotropic drugs in the complex treatment of this disease is gaining increasing importance. An important condition for the successful use of immunocorrectors is their effect not only on the systemic components of the immune system, but also on local factors that determine the formation and development of endometrioid foci. Conclusions. It has been established that the immunological component plays a key role in the etiology and pathogenesis of endometriosis, which is confirmed by the data of modern scientific publications. The immunological direction in the treatment of endometriosis is predicted to undergo intensive development. Surgical treatment of endometriosis and restoration of immune homeostasis of the involved organs are necessary components of the comprehensive management of this category of patients.
- 25 September 2025
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Ukrainian educational and scientific medical space
- No. 1,p. 67-75
Open AccessETIOPATHOGENETIC JUSTIFICATION OF ENDOMETRIOSIS IMMUNOTHERAPY
Introduction. Genital endometriosis (GE) remains a fairly common disease, occurring in 0.5-5% of fertile women and in 25-40% of infertile women. In modern studies, the ability of endometrioid foci to actively resist immune surveillance, which causes changes in the behavior of regulatory cells: T-lymphocytes and macrophages, attracts attention. Aim. Using data from modern literary sources, to study the role of the immunological component in the etiology and pathogenesis of endometriosis and to outline the prospects for immunotherapeutic approaches to solving the problem. Materials and methods. The search and selection of publications, systematic reviews and current recommendations was carried out using the PubMed and Google Scholar databases. Abstracts of publications were studied and articles that did not meet the study criteria were excluded. The full texts of the selected articles were examined for compliance with the study criteria. Results. Ectopic endometrial cells, creating a new microenvironment around themselves and launching protective mechanisms against attacks by lymphocytes and macrophages, demonstrate to us how living microstructures are able to adapt and survive in unusual, even extreme, conditions. In connection with the key role of the immune system in the pathogenesis of GE established in studies, the pathogenetic significance of immunotropic drugs in the complex treatment of this disease is gaining increasing importance. An important condition for the successful use of immunocorrectors is their effect not only on the systemic components of the immune system, but also on local factors that determine the formation and development of endometrioid foci. Conclusions. It has been established that the immunological component plays a key role in the etiology and pathogenesis of endometriosis, which is confirmed by the data of modern scientific publications. The immunological direction in the treatment of endometriosis is predicted to undergo intensive development. Surgical treatment of endometriosis and restoration of immune homeostasis of the involved organs are necessary components of the comprehensive management of this category of patients.
- Open Access
- 24 April 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (2) , 130-138
Quality of life of endometriosis patients: focus on pain syndrome and neurological disorders
Background. Endometriosis has a significant impact on the quality of life of patients, as it is a source of debilitating pain syndrome, leading to depression, anxiety and sleep disorders. Therefore, studying the possibilities of effective treatment of this disease and assessing the quality of life indicators of patients is a relevant clinical task. The purpose was to investigate the quality of life indicators in patients with endometriosis using the assessment of the quality of life index, the presence and intensity of pain syndrome, as well as neurological disorders in dynamics. Materials and methods. One hundred and twenty patients with genital endometriosis aged 19 to 44 years were divided into 2 study groups: in one group, hormone therapy was prescribed after laparoscopic removal of endometrioma, in another — peptide immunocorrection. During clinical monitoring, the quality of life index was assessed, and the effect of treatment on the dynamics of regression of clinical symptoms of the disease and its neurological consequences was analyzed. Results. Before the start of treatment, the quality of life index was at a relatively low level: 41.0 ± 4.8 points in group 1 and 41.0 ± 4.8 points in group 2. In group 1, it reached its maximum 6 months after surgery and was 77.0 ± 5.5 points, which is 75.0 % higher compared to baseline. In group 2, a similar dynamics of an increase in the quality of life index was observed, which at the end of the observation period was 84.0 ± 3.9 points exceeding the baseline by 104.9 %. In both study groups throughout the entire period of clinical monitoring, we observed a decrease in the intensity of the pain syndrome, as well as a gradual decrease in the number of patients complaining of insomnia, depressive disorders and anxiety. Conclusions. Surgical treatment of endometriosis, prescription of hormone therapy and the restoration of immune homeostasis of the involved organs are effective components of the comprehensive management of this category of patients. Reducing the intensity of chronic pain, and subsequently its elimination, inevitably improves the overall condition of patients and their quality of life.
- 24 April 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (2) , 130-138
Open AccessQuality of life of endometriosis patients: focus on pain syndrome and neurological disorders
Background. Endometriosis has a significant impact on the quality of life of patients, as it is a source of debilitating pain syndrome, leading to depression, anxiety and sleep disorders. Therefore, studying the possibilities of effective treatment of this disease and assessing the quality of life indicators of patients is a relevant clinical task. The purpose was to investigate the quality of life indicators in patients with endometriosis using the assessment of the quality of life index, the presence and intensity of pain syndrome, as well as neurological disorders in dynamics. Materials and methods. One hundred and twenty patients with genital endometriosis aged 19 to 44 years were divided into 2 study groups: in one group, hormone therapy was prescribed after laparoscopic removal of endometrioma, in another — peptide immunocorrection. During clinical monitoring, the quality of life index was assessed, and the effect of treatment on the dynamics of regression of clinical symptoms of the disease and its neurological consequences was analyzed. Results. Before the start of treatment, the quality of life index was at a relatively low level: 41.0 ± 4.8 points in group 1 and 41.0 ± 4.8 points in group 2. In group 1, it reached its maximum 6 months after surgery and was 77.0 ± 5.5 points, which is 75.0 % higher compared to baseline. In group 2, a similar dynamics of an increase in the quality of life index was observed, which at the end of the observation period was 84.0 ± 3.9 points exceeding the baseline by 104.9 %. In both study groups throughout the entire period of clinical monitoring, we observed a decrease in the intensity of the pain syndrome, as well as a gradual decrease in the number of patients complaining of insomnia, depressive disorders and anxiety. Conclusions. Surgical treatment of endometriosis, prescription of hormone therapy and the restoration of immune homeostasis of the involved organs are effective components of the comprehensive management of this category of patients. Reducing the intensity of chronic pain, and subsequently its elimination, inevitably improves the overall condition of patients and their quality of life.
- Open Access
- 1 April 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (2) , 206-214
Breast cancer is a threatening scenario resulting from the development of endometriosis and benign breast disease overlap syndrome: literature review
Background. According to the National Cancer Registry of Ukraine, mortality from breast cancer (BC) continues to be at the first places in the structure of oncological pathology among the female population. The overlap syndrome of genital endometriosis (GE) and benign breast disease (BBD) can play a significant role in the development of BC. The purpose: using data from modern literature sources, to consider the overlap syndrome of GE and BBD as a precancerous pattern in the development of BC and outline possible steps to solve the problem. Materials and methods. The search and selection of publications was carried out in the PubMed and Google Scholar databases using the following terms: genital endometriosis, benign breast disease, mastopathy, fibrocystic dysplasia, mastalgia, breast cancer, hormone therapy. Results. A convincing link between endometriosis and fibrocystic disease has been established in fertile women: the prevalence of BBD in patients with endometriosis is 36–38 %. Pilot clinical studies have confirmed that in women with endometriosis who received dienogest at a dose of 20 mg/day orally for 24 weeks, a significant decrease in breast size (p < 0.023) and regression of mastopathic changes were observed when assessing the effect of progestogen on the breast using ultrasound. A slight decrease (p = 0.089) in the maximum diameter of the ducts was observed. At the stages of development of the overlap syndrome of GE and BBD with a confirmed increased risk of BC, a complex pathogenetic matrix is formed, the processes in which are often not linear, but can occur in parallel, demonstrating the diversity and unpredictability of biological events. The high percentage of overlap syndrome of GE and BBD confirms the idea of the unity of the origin of pathological changes in target organs and the synchronous development of benign hyperplastic processes in them. Conclusions. It is advisable to consider hyperplastic diseases as a generalized process in the reproductive system, and to develop single therapeutic tactics when gynecological pathology is combined with breast diseases. The overlap syndrome of GE and BBD, which is a proven factor of increased risk of breast cancer, requires responsible and coordinated teamwork of endocrinologists, mammologists and obstetricians-gynecologists, which is designed to create necessary conditions for a significant improvement in the effectiveness of therapy. The development in the near future of an algorithm for clinical monitoring of patients with overlap syndrome of GE and BBD will be a logical and justified step, because early diagnosis of BC provides better treatment results and an increase in the quality of life of patients.
- 1 April 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (2) , 206-214
Open AccessBreast cancer is a threatening scenario resulting from the development of endometriosis and benign breast disease overlap syndrome: literature review
Background. According to the National Cancer Registry of Ukraine, mortality from breast cancer (BC) continues to be at the first places in the structure of oncological pathology among the female population. The overlap syndrome of genital endometriosis (GE) and benign breast disease (BBD) can play a significant role in the development of BC. The purpose: using data from modern literature sources, to consider the overlap syndrome of GE and BBD as a precancerous pattern in the development of BC and outline possible steps to solve the problem. Materials and methods. The search and selection of publications was carried out in the PubMed and Google Scholar databases using the following terms: genital endometriosis, benign breast disease, mastopathy, fibrocystic dysplasia, mastalgia, breast cancer, hormone therapy. Results. A convincing link between endometriosis and fibrocystic disease has been established in fertile women: the prevalence of BBD in patients with endometriosis is 36–38 %. Pilot clinical studies have confirmed that in women with endometriosis who received dienogest at a dose of 20 mg/day orally for 24 weeks, a significant decrease in breast size (p < 0.023) and regression of mastopathic changes were observed when assessing the effect of progestogen on the breast using ultrasound. A slight decrease (p = 0.089) in the maximum diameter of the ducts was observed. At the stages of development of the overlap syndrome of GE and BBD with a confirmed increased risk of BC, a complex pathogenetic matrix is formed, the processes in which are often not linear, but can occur in parallel, demonstrating the diversity and unpredictability of biological events. The high percentage of overlap syndrome of GE and BBD confirms the idea of the unity of the origin of pathological changes in target organs and the synchronous development of benign hyperplastic processes in them. Conclusions. It is advisable to consider hyperplastic diseases as a generalized process in the reproductive system, and to develop single therapeutic tactics when gynecological pathology is combined with breast diseases. The overlap syndrome of GE and BBD, which is a proven factor of increased risk of breast cancer, requires responsible and coordinated teamwork of endocrinologists, mammologists and obstetricians-gynecologists, which is designed to create necessary conditions for a significant improvement in the effectiveness of therapy. The development in the near future of an algorithm for clinical monitoring of patients with overlap syndrome of GE and BBD will be a logical and justified step, because early diagnosis of BC provides better treatment results and an increase in the quality of life of patients.